High volume Plasma Exchange

Phase 3Biologic

IInstitute of Liver and Biliary Sciences, India

High volume Plasma Exchange is one of 67 biologic programs targeting Chronic Liver Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Liver FailureActive, not recruiting

Liver DiseaseActive, not recruiting

Drug-Induced Liver InjuryNot yet recruiting

Chronic Liver FailurePreclinical

Active, not recruiting

Liver DiseasePreclinical

Active, not recruiting

Drug-Induced Liver InjuryPhase 3

Not yet recruiting

Competition

Competitive Landscape

100 competitors in Liver Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

1 2

Elunate

Mektovi

Sovaldi

Kalydeco

Vertex Pharmaceuticals

Piqray

Balversa

Cibinqo

Dayvigo

Nexavar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug-Induced Liver Injury1 trial

Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·Phase 2/3·NCT06797011·96 enrolled

Liver Disease1 trial

Efficacy and Safety of Plasma Exchange Compared to Standard Medical Therapy in Patients With Severe Drug Induced Liver Injury With or Without Underlying Chronic Liver Disease.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04015570·30 enrolled

Chronic Liver Failure1 trial

High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02719210·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for High volume Plasma Exchange. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High volume Plasma Exchange compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High volume Plasma Exchange. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: IInstitute of Liver and Biliary Sciences, India

High volume Plasma Exchange

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Drug-Induced Liver Injury1 trial

Liver Disease1 trial

Chronic Liver Failure1 trial

References

Drug Info

Quick Facts

Related News